The key component of EMS is insulin dysregulation, which are derangements in the balanced relationship between plasma insulin, glucose and lipids, and manifests clinically as baseline hyperinsulinemia, an exaggerated or prolonged insulin or glucose response post oral or intravenous carbohydrate challenge, tissue insulin resistance, or hypertriglyceridemia [1]. The gene discussed is INS; the disease is hypertriglyceridemia.